Key result
Transvenous ICD implantation precipitates superior vena cava syndrome in a patient with lupus anticoagulant.
Why the study?
Superior vena cava syndrome is a rare but recognized complication after permanent pacemaker implantation, with limited data on its occurrence after transvenous cardioverter defibrillator implantation.
Case Report (n=1)
Highlights SVC syndrome risk after ICD implantation in lupus anticoagulant carriers; leaves open optimal antithrombotic strategies.
Superior vena cava syndrome is a rare, but nevertheless well known complication of permanent pacemaker implantation. Nowadays cardioverter defibrillators are also routinely implanted transvenously. A superior vena cava syndrome occurred in a 48-year-old female 2 years after implantation of cardioverter defibrillator. The clinical problem, in the presence of a predisposing thrombophilic condition (circulating lupus anticoagulant), resolved only partially after treatment with thrombolytics and oral anticoagulation. This syndrome should be recognized as a possible important complication of defibrillator therapy and requires lifelong anticoagulation.
No takes yet. Share an insight, caveat, or question.
Dhondt et al. (1995) conducted a case report in Superior vena cava syndrome (n=1). Implantation of transvenous cardioverter defibrillator was evaluated on Superior vena cava syndrome. Implantation of a transvenous cardioverter defibrillator led to superior vena cava syndrome 2 years post-procedure in a 48-year-old female with circulating lupus anticoagulant.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: